Australia seems poised to gain access to a groundbreaking therapy for obesity: Retatrutide. The dual agonist – working on both GLP-1 and GIP receptors – has remarkable efficacy in clinical trials, indicating meaningful drops in body fat. While regulatory clearance remains with the Therapeutic Goods Administration (TGA), many people struggling o… Read More